

Clinical

Schizophrenia

Bipolar Disorder (Bipolar Mania, Bipolar Depression)

Major Depression

All Indications

Other Indications

Non-clinical

Pharmacokinetic (non-human, human)

Health Technology Assessment (HTA)

General (in Hungarian)

Clinical

Schizophrenia

What is the minimum clinically important change in negative symptoms of schizophrenia? PANSS based post hoc analyses of a phase III clinical trial  **Open access**

Czobor P, Sebe B, Acsai K, Barabassy A, Laszlovszky I, Németh G, Furukawa TA, Leucht S
Front Psychiatry. 2022; 13: 816339. doi.org/10.3389/fpsy.2022.816339

Dosing cariprazine within and beyond clinical trials – recommendations for the treatment of schizophrenia  **Open access**

Rancans E, Dombi ZB, Barabassy A
Front Psychiatry. 2022; 12: 770234. doi.org/10.3389/fpsy.2021.770234

Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases. Letter to the Editor  **Open access**

Németh G, Dombi ZB, Laszlovszky I, Barabácssy Á
Expert Opin Pharmacother. 2022; 23(12): 1467-1468. doi.org/10.1080/14656566.2021.1968827

Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy, and safety  **Open access**

Laszlovszky I, Barabácssy Á, Németh G
Adv Ther. 2021; 38(7): 3652-3673. doi.org/10.1007/s12325-021-01797-5

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms  **Open access**

Demyttenaere K, Leenaerts N, Acsai K, Sebe B, Laszlovszky I, Barabácssy Á, Fonticoli L, Szatmári B, Earley W, Németh G, Correll CU
Eur Psychiatry, 2021; 1-27. doi.org/10.1192/j.eurpsy.2021.2241

[The burden of caring for someone with schizophrenia: A cross country report from Bulgaria, the Czech Republic, Hungary and Russia](#)

Sebe B, Barabácssy Á, Buksa K, Laszlovszky I, Dombi ZB, Németh G, Falkai P
Psychiatria Hungarica. 2021; 36(4): 564-556. PubMed PMID: 34939572

[The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: An observational study](#) Open access

Rancans E, Dombi ZB, Mátrai P, Barabácssy Á, Sebe B, Skrivele I, Németh G
Int Clin Psychopharmacol. 2021; 36(3): 154-161. doi.org/10.1097/YIC.0000000000000351

[The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post-hoc analysis of 3 randomised, placebo-controlled trials](#) Open access

Falkai P, Dombi ZB, Acsai K, Barabácssy Á, Schmitt A, Németh G
CNS Spectrum. 2021; 1-23. doi.org/10.1017/S1092852921000997

[Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies](#) Open access

Barabácssy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G
Neuropsychiatr Dis Treat. 2021; 17: 957-970. doi.org/10.2147/NDT.S301225
[Corrigendum](#): Neuropsychiatr Dis Treat. 2021; 17: 1481. doi.org/10.2147/NDT.S316858

[Cariprazine safety in adolescents and the elderly: Analyses of clinical study data](#) Open access

Szatmári B, Barabácssy Á, Harsányi J, Laszlovszky I, Sebe B, Gál M, Shiragami K, Németh G
Front Psychiatry. 2020; 11: 61. doi.org/10.3389/fpsy.2020.00061

[Cariprazine therapy in the spirit of functionality – new ways in schizophrenia treatment](#) (Published in Hungarian with English abstract)

Laszlovszky I, Barabácssy Á, Németh G
Psychiat Hung. 2020; 35(Suppl 1): 12-26.

[Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies](#) Open access

Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S
Eur Neuropsychopharmacol. 2019; 29(1): 127-136. doi.org/10.1016/j.euroneuro.2018.10.008

[Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data](#) Open access

Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, Patel M, Barabácssy A, Szatmári B, Németh G
Schizophr Res. 2019; 204: 282-288. doi.org/10.1016/j.schres.2018.08.020

[The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors](#) Open access

Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabácssy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G
Eur Psychiatry. 2019; 58: 1-9. doi.org/10.1016/j.eurpsy.2019.01.015

[Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: Understanding negative symptom scores in schizophrenia](#)  Open access

Leucht S, Barabáßy A, Laszlovszky I, Szatmári B, Acsai K, Szalai E, Harsányi J, Earley W, Németh G
Neuropsychopharmacology. 2019; 44(9): 1589-1596. doi.org/10.1038/s41386-019-0363-2

[Long-term remission with cariprazine treatment in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial](#)  Open access

Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W
J Clin Psychiatry. 2019; 80(2): 18m12495. doi.org/10.4088/JCP.18m12495

[Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation](#)  Open access

Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabáßy Á, Patel M, Earley W
Neuropsychiatr Dis Treat. 2019; 15: 2537–2550. doi.org/10.2147/NDT.S210340

[Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study](#)  Open access

Cutler A, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Németh G
CNS Spectrum. 2018; 23(1): 39-50. doi.org/10.1017/S1092852917000220

[Negative symptoms of schizophrenia: Constructs, burden, and management](#)  Open access

Barabáßy A, Szatmári B, Laszlovszky I, Németh G
Psychotic Disorders: An Update; Edited by Federico Durbano, IntechOpen, 2018, pp. 43-62. ISBN 978-953-51-5976-6; doi.org/10.5772/intechopen.73300

[Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial](#)  Open access at Richter website

Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabáßy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW
Lancet. 2017; 389(10074): 1103-1113. doi.org/10.1016/S0140-6736(17)30060-0

[The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis](#)  Open access

Nasrallah H, Earley W, Cutler A, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S
BMC Psychiatry. 2017; 17(1): 305. doi.org/10.1186/s12888-017-1459-z

[Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study](#)  Open access

Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Németh G, Migliore R, Volk S
Psychopharmacology. 2017; 234(2): 199-209. doi.org/10.1007/s00213-016-4450-3

[Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies](#)  Open access

Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM
Int Clin Psychopharmacol. 2017; 32(6): 319-328. doi.org/10.1097/YIC.0000000000000187

[Cariprazine in the treatment of schizophrenia: A proof-of-concept trial](#)  Open access
Durgam S, Litman R, Papadakis K, Li D, Németh G, Laszlovszky I
Int Clin Psychopharmacol. 2016; 31(2): 61-68. doi.org/10.1097/YIC.000000000000110

[The effect of cariprazine on hostility associated with schizophrenia](#)  Open access
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I
J Clin Psychiatry . 2016; 77(1): 109-115. doi.org/10.4088/JCP.15m10192

[Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial](#)  Open access
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA
Schizophr Res. 2016; 176(2-3):264-271. doi.org/10.1016/j.schres.2016.06.030

[Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial](#)  Open access
Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY
J Clin Psychiatry. 2015; 76(12):e1574-1582. doi.org/10.4088/JCP.15m09997

[Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results from an international, phase III clinical trial](#)  Open access
Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S
J Clin Psychopharmacol. 2015; 35(4): 367-373. doi.org/10.1097/JCP.0000000000000346

[An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial](#)  Open access
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I
Schizophr Res. 2014; 152(2-3): 450-457. doi.org/10.1016/j.schres.2013.11.041

Bipolar Disorder (Bipolar Mania, Bipolar Depression)

[Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System](#)  Open access
Heinz Grunze, Réka Cseh, Christoph Born and Ágota Barabácssy
Front Psychiatry. 2021; 12: 803208. doi.org/10.3389/fpsyt.2021.803208

[Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression](#)  Open access
Citrome L, Yatham LN, Patel MD, Barabácssy Á, Hankinson A, Earley WR
J Affect Disord. 2021; 288: 191-198. doi.org/10.1016/j.jad.2021.03.076

[Efficacy of cariprazine in bipolar I depression across patient characteristics: A post hoc analysis of pooled randomized, placebo-controlled studies](#)  Open access
Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN
Int Clin Psychopharmacol. 2021; 36(2): 76-83. doi.org/10.1097/YIC.0000000000000344

[The efficacy of cariprazine on function in patients with bipolar depression: A post hoc analysis of a randomized controlled trial](#)  Open access
Vieta E, Calabrese JR, Whelan J, Tohen M, Earley WR
Curr Med Res Opin. 2021; 37(9): 1635-1643. doi.org/10.1080/03007995.2021.1932446

[Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications](#)

 [Open access](#)

Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W

Prim Care Companion CNS Disord. 2020; 22(5): 20m02611. doi.org/10.4088/PCC.20m02611

[Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies](#)  [Open access](#)

McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM

CNS Spectrum. 2020; 25(4): 502-510. doi.org/10.1017/S1092852919001287

[Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study](#)  [Open access](#)

Earley W, Burgess MV, Khan B, Rekedal L, Suppes T, Tohen M, Calabrese JR

Bipolar Disord. 2020; 22: 372-384. doi.org/10.1111/bdi.12852

[Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial](#)  [Open access](#)

Yatham LN, Vieta E, Earley WR

Int Clin Psychopharmacol. 2020; 35: 147-156. doi.org/10.1097/YIC.0000000000000307

[A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression](#)

 [Open access](#)

Earley WR, Burgess M, Rekedal L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN

J Affect Disord. 2020; 263: 386-395. doi.org/10.1016/j.jad.2019.11.098

[Cariprazine treatment of bipolar depression: A randomized, double blind, placebo-controlled phase 3 study](#)  [Open access](#)

Earley W, Burgess M, Rekedal L, Dickinson R, Szatmari B, Németh G, McIntyre RS, Sachs GS, Yatham LN

Am J Psychiatry. 2019; 176(6): 439-448. doi.org/10.1176/appi.ajp.2018.18070824

[Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials](#)  [Open access](#)

McIntyre RS, Masand PS, Earley W, Patel M

J Affect Disord. 2019; 257: 600-606. doi.org/10.1016/j.jad.2019.07.020

[Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder](#)  [Open access](#)

Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, Yatham LN

J Affect Disord. 2018; 226: 239-244. doi.org/10.1016/j.jad.2017.09.040

[The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study](#)  [Open access](#)

Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G

J Affect Disord. 2018; 225: 350-356. doi.org/10.1016/j.jad.2017.08.040

[Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies](#)  [Open access](#)

Earley W, Durgam S, Lu K, DeBelle M, Laszlovszky I, Vieta E, Yatham LN

J Affect Disord. 2017; 215: 205-212. doi.org/10.1016/j.jad.2017.03.032

[An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression](#)  Open access

Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, Vieta E, Calabrese JR, Yatham LN
Am J Psychiatry. 2016; 173(3): 271-281. doi.org/10.1176/appi.ajp.2015.15020164

[Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial](#)  Open access

Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S
J Affect Disord. 2015; 174: 296-302. doi.org/10.1016/j.jad.2014.11.018

[Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder](#)  Open access

Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S
J Clin Psychiatry. 2015; 76(3): 284-292. doi.org/10.4088/JCP.14m09081

[The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial](#)  Open access

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I
Bipolar Disord. 2015; 17(1): 63-75. doi.org/10.1111/bdi.12238

Major Depression

[Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study](#)

Gary S. Sachs, Paul P. Yeung, Ludmyla Reveda, Arifulla Khan, Julie L. Adams, Maurizio Fava
Am J Psychiatry, 2023; 180(3): 241-251. doi.org/10.1176/appi.ajp.20220504

[Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder](#)  Open access

Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabássy Á, Németh G
Int Clin Psychopharmacol. 2019; 34(2): 76-83. doi.org/10.1097/YIC.0000000000000246

[Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial](#)  Open access

Earley W, Guo H, Németh G, Harsányi J, Thase M
Psychopharmacology Bull. 2018; 48(4): 62-80.

[Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial](#)  Open access

Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Németh G
Int Clin Psychopharmacol. 2018; 33(6): 312-321. doi.org/10.1097/YIC.0000000000000235

[Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients](#)  Open access

Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, Fava M, Montgomery SA
J Clin Psychiatry. 2016; 77(3): 371-378. doi.org/10.4088/JCP.15m10070

All Indications

[Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia](#)

Riccobene T, Riesenberger R, Yeung PP, Earley WR, Hankinson AL

J Child Adolesc Psychopharmacol. 2022; 32(8): 434-443. doi.org/10.1089/cap.2021.0139

[Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists. Editorial](#) Open access

Németh G, Csehi R

Front Psychiatry 2022; 13: 1038627. doi.org/10.3389/fpsy.2022.1038627

[Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia](#)

 Open access

Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR

Neuropsychiatr Dis Treat. 2022; 18: 995-1011. doi.org/10.2147/NDT.S348143

[Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies](#) Open access

Csehi R, Dombi ZB, Sebe B, Molnár MJ

Front. Psychiatry. 2022; 13: 827744. doi.org/10.3389/fpsy.2022.827744

[The Efficacy of Cariprazine on Cognition: A Post Hoc Analysis From Phase II/III Clinical Trials in Bipolar Mania, Bipolar Depression, and Schizophrenia](#)

McIntyre RS, Daniel DG, Vieta E, Laszlovszky I, Goetghebuer PJ, Earley W, Patel M

CNS Spectrum. – in press, 2022; 1-30. doi.org/10.1017/S109285292200013X

[Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis](#) Open access

Durgam S, Earley W, Lu K, Németh G, Laszlovszky I, Volk S, Litman RE

Int J Clin Pract. 2017; 71(12): e13037. doi.org/10.1111/ijcp.13037

Other Indications

[Improving mood and cognitive symptoms in Huntington's disease with cariprazine treatment](#)

 Open access

Molnar MJ, Molnar V, Fedor M, Csehi R, Acsai K, Borsos B, Grosz Z

Front Psychiatry. 2022; 12: 825532. doi.org/10.3389/fpsy.2021.825532

[Wernicke–Korsakoff syndrome associated with mtDNA disease](#) Open access

Jimoh IJ, Sebe B, Balicza P, Fedor M, Pataky I, Rudas G, Gál A, Inczedy-Farkas G, Németh G, Molnár MJ

Ther Adv Neurol Disord. 2020; 13: 1756286420938972. doi.org/10.1177/1756286420938972

Non-clinical

[Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo](#)  Open access

Kiss B, Krámos B, Laszlovszky I

Front. Psychiatry. 2022; 13: 785592. doi.org/10.3389/fpsy.2022.785592

[Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders](#)

 Open access

Kehr J, Wang FH, Ichinose F, Yoshitake S, Farkas B, Kiss B, Adham N

Front. Psychiatry. 2022; 12: 801641. doi.org/10.3389/fpsy.2021.801641

[Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of Autism Spectrum Disorder](#)  Open access

Román V, Adham N, Foley A, Hanratty L, Farkas B, Lendvai B, Kiss B

Psychopharmacol. 2021; 238(9): 2381-2392. doi.org/10.1007/s00213-021-05851-6

[Cariprazine modulates sleep architecture in rats](#)

Nyitrai G, Kiss B, Farkas B, Balázs O, Diószegi P, Lendvai B, Czurkó A

J Psychopharmacol. 2021; 35(3): 303-310. doi.org/10.1177/0269881120981378

[C-N Bond Formation by Consecutive Continuous-Flow Reductions towards A Medicinally Relevant Piperazine Derivative](#)  Open access

Fülöp Z, Bana P, Greiner I, Éles J

Molecules. 2021; 26(7): 2040. doi.org/10.3390/molecules26072040

[Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders](#)

 Open access

Jan Kehr, Fu-Hua Wang, Fumio Ichinose, Shimako Yoshitake, Bence Farkas, Béla Kiss and Nika Adham

Front. Psychiatry. 2022; 12: 801641. doi.org/10.3389/fpsy.2021.801641

[Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin_{1A} receptor neurotransmission in the hippocampus](#)

El Mansari M, Ebrahimzadeh M, Hamati R, Iro CM, Farkas B, Kiss B, Adham N, Blier P

J Psychopharmacol. 2020; 34(10): 1143-1154. doi.org/10.1177/0269881120936891

[The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices](#)

 Open access

Meier MA, Lemercier CE, Kulisch C, Kiss B, Lendvai B, Adham N, Gerevich Z

Br J Pharmacol. 2020; 177(7): 1622-1634. doi.org/10.1111/bph.14923

[The role of dopamine D₃ receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens](#)

Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY;

J Pharmacol Exp Ther. 2019; 371(2): 517-525. doi.org/10.1124/jpet.119.259879

[The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task](#)  Open access

Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B
Psychopharmacology. 2018; 235(5): 1403-1414. doi.org/10.1007/s00213-018-4857-0

[Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity](#)  Open access

Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N
Psychopharmacology. 2018; 235(5): 1593–1607. doi.org/10.1007/s00213-018-4874-z

[Involvement of 5-HT1A and 5-HT2A receptors but not \$\alpha\$ 2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo](#)  Open access

Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P
Mol Pharmacol. 2018; 94(6): 1363-1370. doi.org/10.1124/mol.118.113290

[The novel atypical antipsychotic cariprazine demonstrates dopamine D₂ receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity](#)  Open access

Delcourte S, Ashby CR, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N
CNS Neurosci Ther. 2018; 24(12): 1129-1139. doi.org/10.1111/cns.12867

[Cariprazine exhibits anxiolytic and dopamine D₃ receptor-dependent antidepressant effects in the chronic stress model](#)  Open access

Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS
Int J Neuropsychopharmacol. 2017; 20(10): 788-796. doi.org/10.1093/ijnp/pyx038

[Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine](#)  Open access

Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrum. 2017; 22(6): 484-494. doi.org/10.1017/S1092852916000894

[The chemistry that lead to cariprazine](#) (published in Hungarian with English abstract)  Open access

Domány Gy, Greiner I
Magyar Kémiai Folyóirat 2016; 122: 112-116.

[Discovery of cariprazine \(chemical aspects\)](#) (published in Hungarian)  Open access

Domány Gy
Magyar Kémikusok Lapja 2016; 71: 261-262.

[The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neuro-developmental model for schizophrenia](#)

Watson DJG, King MV, Gyertyán I, Kiss B, Adham N, Fone KC
Eur Neuropsychopharmacol. 2016; 26(2): 208-224. doi.org/10.1016/j.euroneuro.2015.12.020

[Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology](#)  Open access

Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N
Eur Neuropsychopharmacol. 2016; 26(1): 3-14. doi.org/10.1016/j.euroneuro.2015.11.016

[Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices](#)

El-Mallakh RS, Payne RS, Schurr A, Gao Y, Lei Z, Kiss B, Gyertyán I, Adham N
Psychiatry Res. 2015; 229(1-2): 370-373. doi.org/10.1016/j.psychres.2015.05.114

[Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression](#)

Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I
Behav Pharmacol. 2014; 25(5-6): 567-574. doi.org/10.1097/FBP.0000000000000070

[Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor \$\beta\$ -arrestin interactions](#) Open access

Gao Y, Peterson S, Masri B, Hougland MT, Adham N, Gyertyán I, Kiss B, Caron MG and El-Mallakh RS
Pharmacol Res Perspect. 2014; 3(1): e00073. doi.org/10.1002/prp2.73

[Long-term effects of cariprazine exposure on dopamine receptor subtypes](#)

Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrum. 2014; 19(3): 268-277. doi.org/10.1017/S1092852913000680

[Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist \[11C\]-cariprazine: An in vivo positron emission tomography study in non-human primates](#)

Tóth M, Varróné A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B
Synapse. 2013; 67(5): 258-264. doi.org/10.1002/syn.21631

[Cariprazine, a dopamine D3-receptor-preferring partial agonist, block phencyclidine-induced impairments of working memory, attention set shifting, and recognition memory in the mouse.](#)

Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C
Psychopharmacology. 2013; 226(1): 91-100. doi.org/10.1007/s00213-012-2896-5

[Cariprazine \(RGH-188\), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats](#)

Román V, Gyertyán I, Sággy K, Kiss B, Szombathelyi Z
Psychopharmacology. 2013; 226(2): 285-293. doi.org/10.1007/s00213-012-2906-7

[Discovery of cariprazine \(RGH-188\): A novel antipsychotic acting on dopamine D3/D2 receptors](#)

Ágai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt É, Kiss B, Vastag M, Tihanyi K, Sággy K, Lasz J, Gyertyán I, Zájer-Balázs M, Gémesi L, M. Kapás, Z. Szombathelyi
Bioorg Med Chem Lett. 2012; 22(10): 3437-3440. doi.org/10.1016/j.bmcl.2012.03.104

[In vitro and in vivo comparison of \[3H\]\(+\)-PHNO and \[3H\]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites](#)

Kiss B, Hórti F, Bobok A
Synapse. 2011; 65: 467-478. doi.org/10.1002/syn.20867

[Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine \(RGH-188\), in monkey brain measured using positron emission tomography](#)

Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B
Psychopharmacology. 2011; 218(3): 579-587. doi.org/10.1007/s00213-011-2343-z

[RGH-188, a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and pro-cognitive effects in rodents](#)

Gyertyán I, Kiss B, Sággy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Ágai-Csongor É, Domány G, Tihanyi K, Szombathelyi Z
Neurochem Int. 2011; 59(6): 925-935. doi.org/10.1016/j.neuint.2011.07.002

[Cariprazine \(RGH-188\), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile](#)

Kiss B, Horváth A, Némethy Z, Schmidt É, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Ágai-Csongor É, Domány G, Tihanyi K, Adham N, Szombathelyi Z
J Pharmacol Exp Ther. 2010; 333(1): 328-340. doi.org/10.1124/jpet.109.160432

[Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents](#)

Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B
J Pharmaceut Biomed Anal. 2008; 48: 678-684. doi.org/10.1016/j.jpba.2008.06.021

Pharmacokinetic (non-human, human)

[Population pharmacokinetics of cariprazine and its major metabolites](#)  Open access

Periclou A, Phillips L, Ghahramani P, Kapás M, Carrothers T, Khariton T
Eur J Drug Metab Pharmacokin. 2021; 46(1): 53-69. doi.org/10.1007/s13318-020-00650-4

[Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania](#)  Open access

Periclou A, Willavize S, Jaworowicz D, Passarelli J, Carrothers T, Ghahramani P, Durgam S, Earley W, Kapás M, Khariton T
Clin Transl Sci. 2020; 13(2): 362-371. doi.org/10.1111/cts.12720

[Comment on: “Clinical pharmacokinetics of atypical antipsychotics: An update”](#)  Open access

Periclou A, Riccobene T, Kapás M, Laszlovszky I
Clinical Pharmacokinet. 2019; 58: 1215-1216. doi.org/10.1007/s40262-019-00795-9

[Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine](#)  Open access

Kiss B, Némethy Z, Fazekas K, Kurkó D, Gyertyán I, Sággy K, Laszlovszky I, Farkas B, Kirschner N, Bolf-Terjéki E, Balázs O, Lendvai B
Drug Des Devel Ther. 2019; 13: 3229-3248. doi.org/10.2147/DDDT.S188760

[Clinical pharmacology study of cariprazine \(MP-214\) in patients with schizophrenia \(12-week treatment\)](#)  Open access

Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y
Drug Design Develop Ther. 2016; 10: 327-338. doi.org/10.2147/DDDT.S95100

[Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand \[11C\]-\(+\)-PHNO](#)  Open access

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A
Psychopharmacology. 2016; 233: 3503-3512. doi.org/10.1007/s00213-016-4382-y

[Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine](#)

Pásztor Mészáros G, Ágai-Csongor É, Kapás M

J Pharm Biomed Anal. 2008; 48(2): 388-497. doi.org/10.1016/j.jpba.2007.12.016

Health Technology Assessment (HTA)

[Place of care and costs associated with acute episodes and remission in bipolar I disorder](#)

 Open access

McIntyre RS, Higa S, Doan QV, Amari D, Oliveri D, Gillard P, Harrington A

J Med Econ. 2022; 25(1): 1110-1117. doi.org/10.1080/13696998.2022.2120264

[Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine](#)  Open access

Vokó Z, Bitter I, Mersich B, Réthelyi J, Molnár A, Pitter JG, Götze Á, Horváth M, Kóczyán K, Fonticoli L, Lelli F, Németh B

Cost Eff Resour Alloc. 2020; 18: 28. doi.org/10.1186/s12962-020-00224-w

[Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia](#)

Németh B, Bendes R, Nagy B, Götze Á, Kóczyán K, Horváth M, Deák I, Tóth B, Kaló Z

Health Policy Tech. 2019; 8: 84-91. doi.org/10.1016/j.hlpt.2019.01.004

[Population-level QALY gain estimates with the use of cariprazine for patients with negative symptoms of schizophrenia in Hungary](#) (Published in Hungarian with English abstract)  Open access

Bendes R, Németh B, Pitter JG, Kóczyán K, Götze Á, Kaló Z

LAM 2019; 29: 467-475. doi.org/10.33616/LAM.29.045

[Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone](#)  Open access at Richter website

Németh B, Molnár A, Akehurst R, Horváth M, Kóczyán K, Németh G, Götze Á, Vokó Z

J Comp Eff Res. 2017; 6: 639-648. doi.org/10.2217/cer-2017-0024

General (in Hungarian)

[Drugs acting on dopamine D3 receptors: Clinical studies and therapeutic profiles](#) (Published in Hungarian with English abstract)

Laszlovszky I

Gyógyszerészet. 2021; 65: 579-588, Published online: 20 October 2021.

Cariprazine (Reagila®) – a new mechanism of action antipsychotic with unique therapeutic possibilities for the treatment of schizophrenia and other psychiatric dysfunctions (Published in Hungarian with English abstract)

Laszlovszky I, Kiss B, Domány G, Kapás M, Barabássy Á, Szatmári B, Szombathelyi Z, Németh G, Greiner I

Gyógyszerészet. 2020; 64(12): 707-713.

[Dopamine D3 receptors and antipsychotics - Aspects of mechanism of action and pharmacological properties - part I.](#) (Published in Hungarian with English abstract)

Kiss B, Laszlovszky I, Krámos B

Gyógyszerészet. 2020; 64(4): 197-208.

[Dopamine D3 receptors and antipsychotics - Aspects of mechanism of action and pharmacological properties - part II.](#) (Published in Hungarian with English abstract)

Kiss B, Laszlovszky I, Krámos B

Gyógyszerészet. 2020; 64(5): 259-267.

[Cariprazine, a new type – dopamine D₃ receptor preferring – partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms](#) (Published in Hungarian with English abstract)  **Open access**

Laszlovszky I, Kiss B, Barabássy Á, Kapás M, Németh G

Neuropsychopharmacol Hung. 2019; 21(3): 103-118. PubMed PMID: 31537751

In nutshell about cariprazine (Published in Hungarian)

Laszlovszky I, Barabássy Á

Psychiatric and Neurology Times – Hungarian ed. 2018; (5): 26-28.

[Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.](#)

[A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications](#) (Published in Hungarian with English abstract)

Laszlovszky I, Németh G

Gyógyszerészet. 2015; 59: 643-646.